Jazz Pharma (JAZZ) director gains shares from performance award

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc director Bruce C. Cozadd reported equity compensation and related tax withholding transactions in the company’s ordinary shares. On January 16, 2026, he received 35,917 ordinary shares at $0.0 per share, delivered under performance share awards that were originally granted on March 3, 2023 and certified as having met their performance-based vesting requirements on that date.

Also on January 16, 2026, 17,453 ordinary shares were disposed of at a price of $171.16 per share, with the filing explaining that these shares were withheld from the vesting and distribution of the performance share awards to satisfy his tax obligations. Following these transactions, Cozadd directly beneficially owned 411,796 ordinary shares of Jazz Pharmaceuticals.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

COZADD BRUCE C

(Last) (First) (Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4 L2

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	01/16/2026		A(1)		35,917	A	$0.0	429,249	D
Ordinary Shares	01/16/2026		F(2)		17,453	D	$171.16	411,796	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents ordinary shares of the Issuer delivered pursuant to the terms of performance share awards made to the reporting person on March 3, 2023. The performance-based vesting requirements applicable to such awards were satisfied on January 16, 2026, which represents the date on which the level of performance attained was certified.

2. Shares withheld from the vesting and distribution of performance share awards to satisfy the reporting person's tax obligations.

	Bruce C Cozadd	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Jazz Pharmaceuticals (JAZZ) report for Bruce C. Cozadd?

Jazz Pharmaceuticals reported that director Bruce C. Cozadd received 35,917 ordinary shares on January 16, 2026 from the vesting of performance share awards and had 17,453 shares withheld on the same date to cover tax obligations.

How many Jazz Pharmaceuticals (JAZZ) shares does Bruce C. Cozadd own after this Form 4?

After the reported transactions, Bruce C. Cozadd beneficially owned 411,796 ordinary shares of Jazz Pharmaceuticals plc, held directly.

What was the source of the 35,917 Jazz Pharmaceuticals (JAZZ) shares acquired by Bruce C. Cozadd?

The 35,917 ordinary shares were delivered pursuant to performance share awards granted to Bruce C. Cozadd on March 3, 2023, after the performance-based vesting requirements were certified as satisfied on January 16, 2026.

Why were 17,453 Jazz Pharmaceuticals (JAZZ) shares disposed of in Bruce C. Cozadd’s Form 4?

The filing states that the 17,453 ordinary shares were withheld from the vesting and distribution of the performance share awards to satisfy Bruce C. Cozadd’s tax obligations.

What transaction codes were used in Bruce C. Cozadd’s Jazz Pharmaceuticals (JAZZ) Form 4?

The Form 4 lists code A for the acquisition of 35,917 ordinary shares at $0.0 per share, and code F for the disposition of 17,453 ordinary shares at $171.16 per share for tax withholding.

What is Bruce C. Cozadd’s relationship to Jazz Pharmaceuticals (JAZZ)?

The filing identifies Bruce C. Cozadd as a director of Jazz Pharmaceuticals plc and indicates that the Form 4 is filed by one reporting person.